)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
InnoCare Pharma
InnoCare Pharma (9969) investor relations material
InnoCare Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary26 Oct, 2026
Executive summary
Jan–Sep 2026 revenue rose 88.21% YoY to RMB2.099bn; net profit was RMB648.3m versus a RMB72.0m loss, while attributable net profit reached RMB655.7m versus a RMB64.4m loss.
Growth was supported by higher orelabrutinib volumes, new tafasitamab and zurletrectinib sales, and license milestone payments; pipeline progress included 14 ongoing registrational trials and 3 global Phase 3 trials.
Financial highlights
Q3 revenue was RMB962.0m, up 150.60% YoY; Q3 drug sales revenue was RMB530.5m, up 38.59%.
Jan–Sep drug sales revenue rose 41.47% YoY to RMB1.449bn; BD and other revenue was RMB650m, versus RMB91m in the prior-year period.
Jan–Sep attributable net profit excluding non-recurring items was RMB586.0m; Q3 adjusted attributable net profit was RMB399.0m.
Jan–Sep R&D spending rose 16.12% YoY to RMB785.1m; R&D/revenue was 37.40%, down 23.21 percentage points.
Outlook and guidance
2026 target is to sustain profitable performance throughout the year; management expects high-quality growth supported by commercialization and pipeline progress.
Soficitinib AD NDA submission is planned for H1 2027 after safety follow-up; ITP NDA approval is an upcoming milestone, and SLE Phase 3 enrollment is to accelerate.
Mesutoclax 1L CLL/SLL fixed-duration Phase 3 data and NDA submission, and BTKi-treated MCL NDA submission, are expected in H1 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from InnoCare Pharma
- Orelabrutinib drove revenue growth as the pipeline advanced and reported losses narrowed.9969
H2 2023 - Revenue up 55.5% and net profit RMB 239.7M, with robust pipeline and >35% sales growth guidance.9969Q2 2026
- Net profit surged over 600% year-over-year on strong drug sales and milestone payments.9969Q1 2026
- Turned profitable in 2025 with 135% revenue growth and major global pipeline advances.9969Q4 2025
- Revenue up 59.85% YTD Q3 2025, net loss down 74.78%, with strong growth outlook.9969Q3 2025
- Revenue up 74%, net loss down 87%, with strong pipeline and global expansion progress.9969Q2 2025
- Orelabrutinib sales and gross margin rose sharply, with net loss halved year-over-year.9969Q3 2024
- Orelabrutinib sales rose 30%, driving revenue growth, margin gains, and a 37.6% loss reduction.9969H1 2024
- Orelabrutinib sales surged 49.1%, driving revenue growth and narrowing annual loss by 29.9%.9969Q4 2024
Next InnoCare Pharma earnings date
Q4 202625 Mar, 2027
InnoCare Pharma
Next InnoCare Pharma earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
InnoCare Pharma Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for cancer and autoimmune diseases. The company leverages its research and development capabilities to advance targeted therapies, including small molecules and biologics. InnoCare’s pipeline includes investigational treatments addressing hematologic malignancies, solid tumors, and chronic immune-related conditions. The company is headquartered in Beijing, China, and its shares are listed on the HKEX.